The gut microbiota in thrombosis.

Area of Science:

• Microbiome Research
• Cardiovascular Disease
• Thrombosis

Background:

• The gut microbiota is increasingly recognized as an environmental factor influencing thrombotic phenotypes in cardiovascular diseases.
• Existing evidence links specific gut microbial species, antithrombotic therapies' impact on microbial diversity, and preclinical thrombosis models to vascular inflammation and thrombus formation.

Purpose of the Study:

• To review the intricate relationship between the gut microbiota, its metabolites, and the development of thromboembolic diseases.
• To highlight meta-organismal pathways connecting microbial metabolic functions with host immune responses as potential diagnostic and therapeutic targets.

Main Methods:

• Review of sequencing studies identifying gut microbial markers in thrombotic disease patients.
• Analysis of research on the effects of antithrombotic therapies on gut microbial diversity.
• Examination of preclinical mouse models demonstrating the gut microbiota's role in vascular inflammation and thrombosis.

Main Results:

• Gut microbiota composition is associated with thrombotic disease phenotypes.
• Impaired gut barrier function contributes to low-grade inflammation, a factor in thrombosis.
• Microbiota-derived metabolites directly impact vascular cells, promoting thrombus formation.

Conclusions:

• The gut microbiota plays a significant role in the pathogenesis of thromboembolic diseases.
• Meta-organismal pathways involving the gut microbiome represent promising avenues for novel diagnostics and therapeutics in cardiovascular medicine.